PlantForm Corporation receives patent from the European Patent Office.
The patent relates to technology that improves the therapeutic efficacy and utility of antibody fragments by linking them to other antibodies so they remain active in the body for a longer period of time.
“This patent is further evidence of PlantForm innovation as we continue to advance our proprietary, plant-based vivoXPRESS technology system to develop important antibody and protein drugs for a wide range of diseases and life-threatening conditions,” said Doug Cossar, PlantForm’s Vice-President, Research.
PlantForm licenses this technology from the University of Guelph, where it was invented by Dr. J. Christopher Hall, the company’s chief scientific officer.
“It’s gratifying when a patent is issued for one of the University’s inventions, particularly so when it’s associated with a U of G startup company that is creating jobs in Ontario,” says Steve De Brabandere, Associate Director of the University of Guelph’s Research Innovation Office.
PlantForm has an expanding portfolio of patents in six families to protect both the core platform technology and products in development.
Key advantages of the vivoXPRESS technology platform include:
- rapid drug development and production timelines
- high levels of drug expression
- mammalian-type glycosylation (less risk of unwanted immune reactions)
- reduced risk profiles versatility (for new product development)
- unlimited scale-up capability (to respond quickly to increased demand), and
- manufacturing costs as much as 90 per cent lower than those for mammalian cell technology systems.
PlantForm Corporation is a biopharmaceutical company focused on the rapid development and production of specialty antibody and protein drugs using the company’s proprietary vivoXPRESS platform. The company’s pipeline includes trastuzumab for a novel indication in nerve regeneration, a biosimilar version of Lucentis and other niche indication drugs.